CJC-1295 DAC

Overview

CJC-1295 with DAC (Drug Affinity Complex) is a tetra-substituted 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) engineered to dramatically extend plasma half-life through a reactive maleimidoproprionic acid (MPA) linker at Lys₃₀ — the DAC moiety. This lysine-coupled maleimide group reacts with endogenous albumin's free Cys-34 thiol via a Michael addition, creating a non-covalent albumin-binding GHRH analog with a plasma half-life of approximately 6–8 days compared to ~7 minutes for native GHRH.

The extended half-life enables once-weekly research dosing while maintaining continuous elevated GH and IGF-1 levels. The "DAC" designation specifically differentiates this compound from CJC-1295 without DAC (also called Mod GRF 1-29), which lacks the albumin-binding moiety and has a shorter half-life (~30 minutes). Research applications include sustained GH axis stimulation studies, body composition research, bone density investigations, and comparative pharmacokinetics versus shorter-acting GHRH analogs.

Mechanism of Action

• Agonism at pituitary GHRH receptors (GHRHr) stimulating cAMP/PKA signaling and pulsatile GH synthesis and release
• DAC moiety forms a reversible covalent bond with albumin Cys-34, creating a circulating reservoir that slowly releases active peptide
• Extended half-life (~6–8 days) enables sustained GH pulse elevation and IGF-1 upregulation
• Tetra-substitution (Ala₂ → Aib, Ser₈ → D-Ala, Gln₁₆,₂₄ → Ala, Ala₁₅ → Aib) prevents DPP-IV proteolysis that rapidly degrades native GHRH
• Downstream IGF-1 elevation with effects on lean body mass, lipolysis, and bone mineral density in research models

Specifications

Reconstitution

Quality Assurance

Every batch undergoes third-party HPLC testing to verify ≥98% purity. Mass spectrometry confirms molecular identity and DAC conjugation. COA included with every order.